HeartBeam, Inc. (NASDAQ: BEAT) is engaged as a cardiac technology company, which leverages its line of proprietary algorithms to help simply vector electrocardiography (VECG). The company’s platform allows patients and their medical treatment teams to detect heart attacks quickly and begin necessary treatment. HeartBeam is the first and only company to develop a 3D-vector ECG platform that can detect heart attack symptoms at any time. Shares of the medical technology company are rallying 30% through early trading on Thursday, October 6, 2022. Over the past three months, HeartBeam has seen an average daily volume of 3.22 million. However, a volume of 16.4 million shares, or a dollar volume of around $102.83 million, has already exchanged hands through early trading.
Shares of HeartBeam are soaring after the company unveiled a new product to its portfolio, which allows wearable devices, such as smartwatches, to connect to HeartBeam’s platform to enable the devices to provide heart monitoring solutions for the patient and their medical treatment professionals. The new product portfolio also provides the addition of arrhythmia detection capabilities.
With the recent patent issuances to HeartBeam, the product portfolio can now provide the following advantages:
- HeartBeam AIMIGo 3L, a new 3-lead 3D-vector electrocardiogram that is the size of a credit card. The device records X,Y,Z cardiac activities and sends the data over to the patient’s doctor for review. The company plans to file a 510(k) submission to the U.S. Food and Drug Administration during the fourth quarter of 2022.
- Using recently issued patents, HeartBeam will look to integrate both synthesized baseline and symptomatic 12-lead signals to enhance medical professionals’ ability to provide an accurate diagnosis. Atrial fibrillation detection capabilities for the AIMIGo 12L device are planned to be submitted to the FDA via 510(k) submission during the second quarter of 2023.
- Smartwatch connectivity with the HeartBeam platform provides patients and their doctors with another monitoring solution.
“Adding smartwatch connectivity to our platform is a significant development as it extends our portfolio by enabling 24/7 heart monitoring capability,” said Branislav Vajdic, Ph.D., HeartBeam Founder and CEO. “Coupled with our breakthrough AIMIGo solution, we believe the overall HeartBeam system will bring a new and much higher level of diagnostic capability to cardiac patients. We continue to make steady progress in realizing our vision of bringing comprehensive cardiac care to patients anytime, anywhere.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
The post HeartBeam (NASDAQ: BEAT) Unveils Cardiac Wearable Connectivity Feature that Can Turn Smartwatch Devices into Around-the-Clock Heart Monitoring Solutions appeared first on Spotlight Growth.
